{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-077790","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2026-06-25T20:30:12+00:00","discovered_at":"2026-06-25T20:31:09.447492+00:00","generated_at":"2026-06-25T20:31:56.170208+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Protalix shareholders approve director elections, executive compensation, stock plan increase, auditor ratification","bullets":["Elected eight directors: each with >28.7M votes; broker non-votes 10.7M for each.","Advisory approval of executive compensation: 28.4M for, 6.7M against, 0.2M abstain.","Approved stock plan amendment increasing authorized shares from 17.5M to 21.0M shares (28.2M for, 7.0M against).","Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2026: 42.96M for, 2.0M against, 1.0M abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-077790","json":"https://secwatch.observer/filing/0001104659-26-077790.json","markdown":"https://secwatch.observer/filing/0001104659-26-077790.md","text":"https://secwatch.observer/filing/0001104659-26-077790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/0001104659-26-077790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/plx-20260625x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:31:56.170208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}